ATE350057T1 - Impfstoffzusammesetzung - Google Patents

Impfstoffzusammesetzung

Info

Publication number
ATE350057T1
ATE350057T1 AT01976380T AT01976380T ATE350057T1 AT E350057 T1 ATE350057 T1 AT E350057T1 AT 01976380 T AT01976380 T AT 01976380T AT 01976380 T AT01976380 T AT 01976380T AT E350057 T1 ATE350057 T1 AT E350057T1
Authority
AT
Austria
Prior art keywords
vaccine composition
pharmaceutical composition
composition
antigen
hiv
Prior art date
Application number
AT01976380T
Other languages
English (en)
Inventor
Jean Haensler
Christian Marcel Hurpin
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE350057T1 publication Critical patent/ATE350057T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Motorcycle And Bicycle Frame (AREA)
AT01976380T 2000-10-06 2001-10-08 Impfstoffzusammesetzung ATE350057T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0012808A FR2814958B1 (fr) 2000-10-06 2000-10-06 Composition vaccinale

Publications (1)

Publication Number Publication Date
ATE350057T1 true ATE350057T1 (de) 2007-01-15

Family

ID=8855083

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01976378T ATE295180T1 (de) 2000-10-06 2001-10-08 Zubereitung zur immunisierung gegen den aids- virus
AT01976380T ATE350057T1 (de) 2000-10-06 2001-10-08 Impfstoffzusammesetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01976378T ATE295180T1 (de) 2000-10-06 2001-10-08 Zubereitung zur immunisierung gegen den aids- virus

Country Status (12)

Country Link
US (3) US20030190326A1 (de)
EP (2) EP1326636B1 (de)
AT (2) ATE295180T1 (de)
AU (2) AU2001295673A1 (de)
CA (1) CA2424836A1 (de)
CY (1) CY1105943T1 (de)
DE (2) DE60125797T2 (de)
DK (1) DK1326636T3 (de)
ES (2) ES2275738T3 (de)
FR (1) FR2814958B1 (de)
PT (2) PT1326635E (de)
WO (2) WO2002028427A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
ES2311478T3 (es) * 1999-11-19 2009-02-16 Csl Limited Composiciones de vacuna contra el hcv.
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
ES2314099T3 (es) * 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CA2503693A1 (en) * 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
JP2006512927A (ja) * 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
EP1608403A2 (de) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
WO2005090968A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
CA2572427A1 (en) * 2004-07-18 2006-01-18 Heather L. Davis Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
FR2881050B1 (fr) * 2005-01-25 2007-02-23 Sanofi Pasteur Sa Dcchol chez les nouveaux-nes
US20060165717A1 (en) * 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
CN101268101A (zh) * 2005-07-07 2008-09-17 科利制药集团公司 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
CN101517082B (zh) 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
AU2010230073B2 (en) 2009-03-23 2016-05-26 Pin Pharma, Inc. Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides
EP3052127A1 (de) 2013-10-04 2016-08-10 PIN Pharma, Inc. Immunstimulierende hiv-tat-derivierende polypeptide zur verwendung bei der krebsbehandlung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2781160B1 (fr) * 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
EP2286792A1 (de) * 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Mikroemulsionen mit einer adsorbierenden Oberfläche, enthaltend eine Mikrotropfenemulsion
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CN100368020C (zh) * 1999-08-27 2008-02-13 不列颠哥伦比亚大学 用于刺激细胞因子分泌和诱导免疫应答的组合物
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
DE60110822T2 (de) 2006-05-11
US20050118188A1 (en) 2005-06-02
WO2002028428A2 (fr) 2002-04-11
US20040038922A1 (en) 2004-02-26
WO2002028427A3 (fr) 2003-03-20
DE60110822D1 (de) 2005-06-16
EP1326635A2 (de) 2003-07-16
WO2002028427A2 (fr) 2002-04-11
AU2001295673A1 (en) 2002-04-15
WO2002028428A3 (fr) 2003-02-20
US20030190326A1 (en) 2003-10-09
PT1326635E (pt) 2005-08-31
FR2814958A1 (fr) 2002-04-12
DK1326636T3 (da) 2007-04-30
EP1326636A2 (de) 2003-07-16
ES2240526T3 (es) 2005-10-16
FR2814958B1 (fr) 2003-03-07
CA2424836A1 (en) 2002-04-11
CY1105943T1 (el) 2011-04-06
EP1326635B1 (de) 2005-05-11
AU2001295671A1 (en) 2002-04-15
DE60125797D1 (de) 2007-02-15
ES2275738T3 (es) 2007-06-16
PT1326636E (pt) 2007-02-28
EP1326636B1 (de) 2007-01-03
ATE295180T1 (de) 2005-05-15
DE60125797T2 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
DK1326636T3 (da) Vaccinesammensætning
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
EP0634937A1 (de) Impfstoffe die nicht ionische tensid vesikeln enthalften.
BRPI0113155B8 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
EP1301208A4 (de) Impfstoff
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
ES2155510T3 (es) Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
BR0211181A (pt) Formulação vacinal
NO953311D0 (no) Anvendelse av anti-helmint-vaksiner ved kontroll av parasittsykdom i forbindelse med tap av naturlig immunitet
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections
DE60216958D1 (de) Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen
FR2818648B1 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
FI893346A0 (fi) Icke-reverterande rna-virus.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326636

Country of ref document: EP